Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Ginsberg

Showing results (291-300 of 312) with videos related to

Pageof 32
Sort By:
Clinical Pharmacology and Therapeutics|July 25, 2017
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 DiabetesDaniel M Rotroff, Sonja S Pijut, Skylar W Marvel, et al.
Journal of Lipid Research|March 19, 2017
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EJohn S Millar, Michael E Lassman, Tiffany Thomas, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
JAMA Cardiology|December 29, 2016
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 DiabetesMarshall B Elam, Henry N Ginsberg, Laura C Lovato, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
The Journal of Clinical Investigation|May 12, 2015
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinGissette Reyes-Soffer, John S Millar, Colleen Ngai, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal|September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis SocietyHenry N Ginsberg, Chris J Packard, M John Chapman, et al.
Hepatology (Baltimore, Md.)|September 2, 2022
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretionWillemien van Zwol, Antoine Rimbert, Justina C Wolters, et al.
Pageof 32

Showing results (291-300 of 312) with videos related to

Sort By:
Pageof 32
Clinical Pharmacology and Therapeutics|July 25, 2017
Genetic Variants in HSD17B3, SMAD3, and IPO11 Impact Circulating Lipids in Response to Fenofibrate in Individuals With Type 2 DiabetesDaniel M Rotroff, Sonja S Pijut, Skylar W Marvel, et al.
Journal of Lipid Research|March 19, 2017
Effects of CETP inhibition with anacetrapib on metabolism of VLDL-TG and plasma apolipoproteins C-II, C-III, and EJohn S Millar, Michael E Lassman, Tiffany Thomas, et al.
The American Journal of Cardiology|December 17, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemiaJean-Charles Fruchart, Frank Sacks, Michel P Hermans, et al.
JAMA Cardiology|December 29, 2016
Association of Fenofibrate Therapy With Long-term Cardiovascular Risk in Statin-Treated Patients With Type 2 DiabetesMarshall B Elam, Henry N Ginsberg, Laura C Lovato, et al.
Diabetes & Vascular Disease Research|October 30, 2008
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patientJean-Charles Fruchart, Frank M Sacks, Michel P Hermans, et al.
The Journal of Clinical Investigation|May 12, 2015
Anacetrapib lowers LDL by increasing ApoB clearance in mildly hypercholesterolemic subjectsJohn S Millar, Gissette Reyes-Soffer, Patricia Jumes, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|March 12, 2016
Cholesteryl Ester Transfer Protein Inhibition With Anacetrapib Decreases Fractional Clearance Rates of High-Density Lipoprotein Apolipoprotein A-I and Plasma Cholesteryl Ester Transfer ProteinGissette Reyes-Soffer, John S Millar, Colleen Ngai, et al.
The Lancet. Diabetes & Endocrinology|October 5, 2019
Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statementRobert A Hegele, Jan Borén, Henry N Ginsberg, et al.
European Heart Journal|September 2, 2021
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies-a consensus statement from the European Atherosclerosis SocietyHenry N Ginsberg, Chris J Packard, M John Chapman, et al.
Hepatology (Baltimore, Md.)|September 2, 2022
Loss of hepatic SMLR1 causes hepatosteatosis and protects against atherosclerosis due to decreased hepatic VLDL secretionWillemien van Zwol, Antoine Rimbert, Justina C Wolters, et al.
Pageof 32